Intellectual Property India Publishes Patent Application for 'Bifunctional Compounds Capable Of Degrading Androgen Receptors' Filed by Astrazeneca Ab

MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202517097253 A) filed by Astrazeneca Ab, Sodertalje, Sweden, on Oct. 8, for 'bifunctional compounds capable of degrading androgen receptors.'

Inventor(s) include Astles, Peter; and Scott, James.

The application for the patent was published on Nov. 21, under issue no. 47/2025.

According to the abstract released by the Intellectual Property India: "A compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein: X1 is CH or N; p is 0, 1 or 2; where: each R1 is a substituent on any C atom and is independently selected from F, Cl, C1-3alkyl and C1-3 alkoxy, wherein said C1-3alkyl and C1-3alkoxy may be independently optionally substituted by one or more F; RN is selected from H and Me; n is 0, 1 or 2; m is 0 or 1; Q1 is CH or N; when n & m are both other than 0, Q2 is CH or N; when n & m are both 0, Q2 is CH; when n is 0 or 1, Q3 is CH; when n is 2 and Q2 is N, Q3 is CH; when n is 2 and Q2 is CH, Q3 is CH or O; R2a and R2b are substituents on the same or different C atoms other than at Q1 or Q2, each independently selected from H, F and C1-3alkyl, or R2a & R2b together form a -(CH2)r- group where r is 1, 2 or 3; Q4 is a single bond or -NR4C(=O); R4 is H or Me; 0, 1 or 2 of Y1, Y2, Y3, Y4 & Y5 is/are N, and are otherwise C; each R3 is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5, and is independently selected from F, Cl, CN, C1-3,alkyl and C1-3 alkoxy. wherein said C1-3 alkyl and C1-3 alkoxy may be independently optionally substituted by one or more F; q is 0, 1 or 2; wherein Linker is attached at any available C atom at Y4 & Y5; Linker is a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment 'a' and 'b' and a length of from 5 to 26 atoms between 'a' and 'b'; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; and W is an E3 ubiquitin ligase cereblon binder unit."

The patent application was internationally filed on Mar. 08, 2024, under International application No.PCT/IB2024/052251.

Disclaimer: Curated by HT Syndication.